THRESHOLD COMPLETES ENROLLMENT IN TWO CANCER DRUG TRIALS

Threshold Pharmaceuticals announced it has completed enrollment in a Phase III trial evaluating glufosfamide for the potential second-line treatment of pancreatic cancer, along with a Phase II trial evaluating glufosfamide in combination with gemcitabine for the potential first-line treatment of pancreatic cancer.

The Phase III trial will evaluate approximately 300 previously treated patients with locally advanced and/or metastatic pancreatic cancer who receive best supportive care (BSC) or glufosfamide once every three weeks plus BSC. Best supportive care includes all medical or surgical interventions that a pancreatic cancer patient should receive to palliate the cancer but excludes treatment with systemic therapies intended to kill the cancer cells. The primary endpoint of this trial is overall survival.

The Phase II trial will evaluate up to 28 previously untreated patients who receive the standard dose of gemcitabine weekly for three of every four weeks plus glufosfamide administered once every four weeks. In addition to safety, the trial will investigate the efficacy of glufosfamide in combination with gemcitabine as determined by response rate, duration of response, progression-free survival, overall survival, six- and 12-month survival and change in serum tumor marker levels.